Idiopathic Pulmonary Fibrosis clinical trials
The registry lists 577 studies for Idiopathic Pulmonary Fibrosis across more than 10 countries. 124 are recruiting or about to start. 504 of them are mainly about Idiopathic Pulmonary Fibrosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its narrower condition Idiopathic Interstitial Pneumonias too: 584 studies, 124 open.
ClinicalTrials.gov finds 640 studies for Idiopathic Pulmonary Fibrosis. How that becomes 574 here
This page counts the studies the registry files under Idiopathic Pulmonary Fibrosis, and those it files under no condition that list Idiopathic Pulmonary Fibrosisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 640Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −7Filed under a narrower condition, counted on its own pageIdiopathic Interstitial Pneumonias 7
- −59Match it another way42 name it in the title and 17 by a synonym or other text the search reads.
- 574The count on this page3 of them list Idiopathic Pulmonary Fibrosis in their own words; the registry filed them under no condition.
Get an email when these change. Save the Idiopathic Pulmonary Fibrosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Boehringer Ingelheim (36) · Hoffmann-La Roche (16) · Royal Brompton & Harefield NHS Foundation Trust (11) · Bristol-Myers Squibb (9) · GlaxoSmithKline (7) · Assistance Publique - Hôpitaux de Paris (7) · Duke University (7) · Genentech, Inc. (7)
What is being tested here
Drugs under test in Idiopathic Pulmonary Fibrosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Pirfenidone | 2 | 6 | 21 |
| Nalbuphine | 2 | 2 | 5 |
| Rentosertib | 2 | 1 | 4 |
| Rituximab | 2 | 0 | 2 |
| Immunoglobulins, Intravenous | 2 | 1 | 2 |
| Immunoglobulin G | 2 | 1 | 2 |
| TDI01 | 2 | 1 | 2 |
| Nintedanib | 1 | 2 | 16 |
| Yinfenidone | 1 | 1 | 6 |
| Admilparant | 1 | 2 | 5 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · Opioids 2 open · Endothelin receptor antagonists 9
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) · Phase 3 · Guangzhou JOYO Pharma Co., Ltd
- Apr 2027A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast · Phase 3 · Boehringer Ingelheim
- Aug 2027Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets · Phase 3 · Trevi Therapeutics
- Nov 2026A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis · Calluna Pharma AS
- Nov 2026IPF Longitudinal Natural History Study · Assiut University
- Nov 2026A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers. · Shanghai Synvida Biotechnology Co.,Ltd.
- Dec 2026AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF · Avalyn Pharma Inc.
- Dec 2026Photon-counting CT Scan vs Standard HRCT Scan in the Identification of Idiopathic Pulmonary Fibrosis · Istituto Clinico Humanitas
- Dec 2026Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis · University of Virginia
- Dec 2026The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study · University of Edinburgh
Who these studies take
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger. 3 (3%) take children under 18. 0 (0%) are for women only and 1 (1%) for men only; 15 (17%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (3%) | 3 (3%) |
| 18 | 47 (55%) | 47 (55%) |
| 30 | 53 (62%) | 54 (63%) |
| 40 | 82 (95%) | 83 (97%) |
| 50 | 84 (98%) | 85 (99%) |
| 65 | 81 (94%) | 81 (94%) |
| 75 | 80 (93%) | 80 (93%) |
| 85 | 69 (80%) | 69 (80%) |
Across all 577 studies, recruiting or not: 13% stop at 75 or younger and 8% at 65; 7% take children; <1% are for women only and 1% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Idiopathic Pulmonary Fibrosis studies take
Of 76 phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 30 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 12 mo5–23 · 75 studies | 10 mo5–16 · 60 studies | — |
| Phase 2 | 30 mo21–50 · 76 studies | 26 mo20–48 · 63 studies | — |
| Phase 3 | 35 mo27–60 · 24 studies | — | — |
| Interventional, no phase | 26 mo14–53 · 52 studies | — | 27 mo14–53 · 49 studies |
| Observational | 51 mo29–96 · 88 studies | — | 58 mo29–102 · 74 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting1
- Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPFOct 16, 2026NCT06914713
Results posted1
Stopped1
- Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPFTerminatedOct 20, 2026NCT05016817
Newly registered6
- A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary FibrosisNov 12, 2026NCT07933133
- A Phase Ⅱa Study of ND-003 Tablets in Patients With Idiopathic Pulmonary FibrosisNov 10, 2026NCT07929948
- A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard TreatmentNov 9, 2026NCT07926321
- Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary FibrosisNov 5, 2026NCT07919015
- A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary FibrosisNov 2, 2026NCT07909655
Show 1 moreShow fewer
Studies
Recruiting first, then most recently updated. Showing 50 of 577. Browse all 577 → or search them.
- A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard TreatmentNot yet recruitingNCT07926321Phase 29 countries
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) TabletsRecruitingNCT07671911Phase 31 country
- Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisRecruitingNCT07284459Phase 219 countries
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) TabletsRecruitingNCT07868419Phase 31 country
- Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes RegistryRecruitingNCT019155111 country
- A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07933133Phase 21 country
- A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT06968845Phase 27 countries
- A Phase Ⅱa Study of ND-003 Tablets in Patients With Idiopathic Pulmonary FibrosisEnrolling by invitationNCT07929948Phase 21 country
- RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesRecruitingNCT07002034Phase 21 country
- Senicapoc in Patients With Worsening Fibrotic Interstitial Lung DiseaseRecruitingNCT06714123Phase 23 countries
- An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)RecruitingNCT06951217Phase 213 countries
- Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary FibrosisRecruitingNCT079190151 country
- A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07909655Phase 21 country
- Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary FibrosisNot yet recruitingNCT07441408Phase 327 countries
- A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.RecruitingNCT07652658Phase 223 countries
- Collection of Airway, Blood and/or Urine Specimens From Subjects for Research StudiesRecruitingNCT017763981 country
- Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07284602Phase 32 countries
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07876284Phase 1
- Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialRecruitingNCT07482917Not applicable1 country
- Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary FibrosisNot yet recruitingNCT07674745Phase 21 country
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseaseEnrolling by invitationNCT04905693Phase 318 countries
- Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung DiseasesRecruitingNCT06189820Phase 21 country
- A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary FibrosisRecruitingNCT07516951Phase 24 countries
- Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPFRecruitingNCT06914713Not applicable1 country
- Study of ORJ-001 for the Treatment of IPFRecruitingNCT07869147Phase 21 country
- AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPFRecruitingNCT07194382Phase 27 countries
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Phase 31 country
- Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote MonitoringRecruitingNCT07673237Not applicable1 country
- A Trial of AGMB-447 in Participants With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07862634Phase 2
- Daoyin Technique for Improving Exercise Endurance in IPFRecruitingNCT07019714Not applicable1 country
- Pulmonary Fibrosis Foundation Community RegistryRecruitingNCT053825721 country
- Inspiratory Flow Rate Capability in Pulmonary Fibrosis PatientsRecruitingNCT078202541 country
- Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07679893Phase 21 country
- Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary FibrosisNot yet recruitingNCT07520110Phase 31 country
- Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary FibrosisRecruitingNCT07230288Phase 217 countries
- Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT05571059Phase 21 country
- Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT003738411 country
- Photon-counting CT Scan vs Standard HRCT Scan in the Identification of Idiopathic Pulmonary FibrosisRecruitingNCT077906141 country
- Blood Cell Count Derived Inflammatory Indexes in Acute Exacerbation of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07783230
- A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.RecruitingNCT06267183Early Phase 11 country
- Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary FibrosisRecruitingNCT04362644Phase 11 country
- Dose-Escalation Study of Artesunate Patients With IPFRecruitingNCT05988463Phase 11 country
- H01 in Adults With Interstitial Lung Disease (The SOLIS Study)RecruitingNCT06325696Phase 21 country
- Predictors of Pulmonary Embolism in Interstitial Lung Disease With Worsening SymptomsNot yet recruitingNCT07728448
- Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07728721Phase 2
- Finger Versus Earlobe Pulse Oximetry During the 6-Minute Walk Test in Interstitial Lung DiseaseRecruitingNCT077238721 country
- New Diagnostic Approaches in the Management of Inflammatory Lung DiseasesNot yet recruitingNCT07723638Not applicable
- Antifibrotic Therapy Decision-Making in Pulmonary FibrosisNot yet recruitingNCT077225071 country
- A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary FibrosisNot yet recruitingNCT07719023Phase 31 country
- Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary NeoplasiaRecruitingNCT07707245Not applicable1 country